机构：[1]Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.临床科室血液内科河北医科大学第四医院[2]Department of Lymphoma Medicine, Beijing Cancer Hospital, Beijing, China.[3]Department of Oncology, Affiliated Hospital of Medical College of Qingdao University, Qingdao, China.[4]Department of Hematology, Qilu Hospital, Shandong University, Jinan, China.[5]Department of Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.[6]Department of Hematology, Second Affiliated Hospital of Kunming Medical University, Kunming, China.[7]Department of Hematology, Guizhou People's Hospital, Guizhou, China.[8]Department of Hematology, Hainan Provincial People's Hospital, Hainan, China.[9]Department of Hematology, General Hospital of Tianjin Medical University, Tianjin, China.[10]Department of Hematology, Changzhou First People's Hospital, Changzhou, China.[11]Department of Lymphoma Medicine, Beijing Cancer Hospital, Beijing, China - cui56788@163.com.
第一作者机构：[1]Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
推荐引用方式(GB/T 7714)：
Gao Yuhuan,Xie Yan,Liu Lihong,et al.Efficacy and safety of CDOP regimen with pegylated liposomal doxorubicin ± rituximab in treating diffuse large B-cell lymphoma.[J].MINERVA MEDICA.2021,112(2):310-312.doi:10.23736/S0026-4806.19.06236-0.
APA：
Gao Yuhuan,Xie Yan,Liu Lihong,Xue Hongwei,Hou Ming...&Zhu Jun.(2021).Efficacy and safety of CDOP regimen with pegylated liposomal doxorubicin ± rituximab in treating diffuse large B-cell lymphoma..MINERVA MEDICA,112,(2)
MLA：
Gao Yuhuan,et al."Efficacy and safety of CDOP regimen with pegylated liposomal doxorubicin ± rituximab in treating diffuse large B-cell lymphoma.".MINERVA MEDICA 112..2(2021):310-312
